EICHOR
● Not Yet Recruiting
Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC
Condition: Bladder Cancer · Sponsor: Chinese University of Hong Kong
About this study
This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-year BCG therapy, in patients with intermediate-risk or high-risk NMIBC.
This description comes directly from the study's public registry record.
Talk to the study team
Yuen Chun Jeremy TEOH, MD · 35053933 · jeremyteoh@surgery.cuhk.edu.hk
Yuen Chun Jeremy TEOH
Always discuss trial participation with your own doctor first.
Locations (2)
| Prince of Wales Hospital | Hong Kong, Hong Kong | — |
| North District Hospital | Sheung Shui, Hong Kong | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07724886